Bromide

Bromide

SCHEMBL1634339

Br.CCCC(CC(c1ccccc1)(c1ccccc1)c1ccccc1)C(=O)OP

nearest known ligand 0.38

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

ACHEADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3APH1AAPH1BCHRM2CHRM3EZH2GRIN2AHTR1AHTR1BHTR1DHTR1FHTR3ANCSTNP2RY12PSEN1PSEN2PSENENSIGMAR1SLC6A2SLC6A3SLC6A4

The experimentally established mechanism targets of Bromide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GRIN2A known ✓ Q12879 2/20 0.37
CHRM3 known ✓ P20309 1/20 0.34
ADRA1A known ✓ P35348 1/20 0.34
SLC6A3 known ✓ Q01959 1/20 0.34
KIF11 P52732 7/20 0.38
GRIN2D O15399 2/20 0.37
GRIN1 Q05586 2/20 0.37
GRIN2B Q13224 2/20 0.37
GRIN2C Q14957 2/20 0.37
OPRM1 P35372 2/20 0.37
KCNH2 Q12809 2/20 0.37
DRD3 P35462 2/20 0.37
POLB P06746 1/20 0.37
CACNA1F O60840 1/20 0.37
ABCB1 P08183 1/20 0.37
CYP2B6 P20813 1/20 0.37
DRD4 P21917 1/20 0.37
OPRD1 P41143 1/20 0.37
OPRK1 P41145 1/20 0.37
CACNA1D Q01668 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Bromide SCHEMBL1634842 0.88 KCNH2 (0.39) KIF11GRIN2DGRIN1GRIN2AGRIN2B
Bromide SCHEMBL1634342 0.82 DRD3 (0.47) KIF11GRIN2DGRIN1GRIN2AGRIN2B
SCHEMBL1635913 0.82 DRD3 (0.50) KIF11GRIN2DGRIN1GRIN2AGRIN2B
Bromide SCHEMBL1634846 0.72 CYP1A2 (0.44) KIF11GRIN2DGRIN1GRIN2AGRIN2B
SCHEMBL9071224 0.72 HDAC1 (0.50) KCNH2DRD3HDAC1HDAC2HDAC3
SCHEMBL1633684 0.72 CYP1A2 (0.47) KIF11GRIN2DGRIN1GRIN2AGRIN2B
SCHEMBL10642480 0.68 CYP2C19 (0.42) KIF11ALDH1A1KMT2AMDM4MDM2
SCHEMBL2731191 0.66 CA2 (0.52) KCNH2DRD3HDAC1HDAC2HDAC3
SCHEMBL7914370 0.65 HDAC1 (0.54) DRD3POLBMEN1ALDH1A1KMT2A
SCHEMBL9537112 0.65 KIF11 (0.53) KIF11KMT2AMDM4MDM2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7932290-B2 Method for the treatment of metabolic disorders WELLSTAT BIOLOGICS CORPORATION (US) 2011-04-26 US disclosed
EP-2266946-A2 Compound For The Treatment Of Metabolic Disorders Wellstat Therapeutics Corporation (US) 2010-12-29 EP disclosed
US-20100087541-A1 COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS WELLSTAT THERAPEUTICS CORPORATION (US) 2010-04-08 US disclosed
EP-1618086-B1 COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS WELLSTAT THERAPEUTICS CORP (US) 2009-12-02 EP disclosed
US-7615575-B2 Compounds for the treatment of metabolic disorders WELLSTAT THERAPEUTICS CORPORATION (US) 2009-11-10 US disclosed
US-7605181-B2 Method for the treatment of metabolic disorders Wellstat Therapeutics Orporation (US) 2009-10-20 US disclosed
US-7361686-B2 Compounds for the treatment of metabolic disorders WELLSTAT THERAPEUTICS CORPORATION (US) 2008-04-22 US disclosed
US-20080015254-A1 COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS WELLSTAT THERAPEUTICS CORPORATION (US) 2008-01-17 US disclosed
US-20070105955-A1 Compounds for the treatment of metabolic disorders PHARMA CINQ, LLC 2007-05-10 US disclosed
EP-1618086-A4 COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS WELLSTAT THERAPEUTICS CORP (US) 2007-05-09 EP disclosed
EP-1601251-A4 COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS WELLSTAT THERAPEUTICS CORP (US) 2007-03-28 EP disclosed
US-20060247309-A1 Compounds for the treatment of metabolic disorders PHARMA CINQ, LLC 2006-11-02 US disclosed
EP-1618086-A2 COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS Wellstat Therapeutics Corporation (US) 2006-01-25 EP disclosed
EP-1601251-A2 COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS Wellstat Therapeutics Corporation (US) 2005-12-07 EP disclosed
WO-2004093806-A2 COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS WELLSTAT THERAPEUTICS CORPORATION (US) 2004-11-04 WO disclosed
WO-2004073611-A2 COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS WELLSTAT THERAPEUTICS CORPORATION (US) 2004-09-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100087541-A1 COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS CPT1B, FABP1, CPT1A GRIN2A 4233/4885CHRM3 735/4885ADRA1A 442/4885
US-20080015254-A1 COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS CPT1B, FABP1, CPT1A GRIN2A 4233/4885CHRM3 735/4885ADRA1A 442/4885
US-20070105955-A1 Compounds for the treatment of metabolic disorders CPT1B, FABP1, CPT1A GRIN2A 4036/4885CHRM3 715/4885ADRA1A 450/4885
US-20060247309-A1 Compounds for the treatment of metabolic disorders CPT1B, CPT1A, FABP1 GRIN2A 4440/4885CHRM3 1810/4885ADRA1A 819/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.